Trials / Completed
CompletedNCT02317484
Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 231 (actual)
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Academic / Other
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate clinical efficacy and safety of Sodium Glucose Co-transporter 2 (SGLT2) inhibitor, ipragliflozin, at doses of 50mg and 100mg, for Type II Diabetes under usual care. It is also to investigate and analyze the exploratory influential factor of ipragliflozin treatment on clinical efficacy and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ipragliflozin (SGLT2 inhibitor) |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2017-11-21
- Completion
- 2018-02-28
- First posted
- 2014-12-16
- Last updated
- 2018-04-17
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02317484. Inclusion in this directory is not an endorsement.